Intermediate Risk Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Intermediate Risk clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 3

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

Intermediate Risk Non-Muscle Invasive Bladder Cancer
Ferring Pharmaceuticals454 enrolled77 locationsNCT06510374
Recruiting
Phase 2

Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML

Acute Myeloid LeukemiaIntermediate Risk Acute Myeloid LeukemiaFLT3 Internal Tandem Duplication Positive+1 more
First Affiliated Hospital of Zhejiang University25 enrolled1 locationNCT07259707
Recruiting
Not Applicable

Addition of Focal Boost to Primary Radiotherapy for Prostate Cancer in 12 or 20 Fractions

Locally Advanced Prostate CancerProstate Cancer Patients Undergoing External Radiation and Seed ImplantationHigh Risk Localised Prostate Carcinoma+1 more
Rigshospitalet, Denmark1,016 enrolled3 locationsNCT07343349
Recruiting
Not Applicable

The PRECISION Study: 3 Fractions of Prostate SBRT and RayPilot HypoCath Image Guidance

Localized Prostate CancerLow-Risk Prostate CancerIntermediate Risk Prostate Cancer
NHS Lothian100 enrolled1 locationNCT06117059
Recruiting
Not Applicable

Micro-ultrasound-Guided Focal Laser Ablation for Intermediate-Risk Prostate Cancer: Safety & Effectiveness

Prostate Cancer (Adenocarcinoma)Low and Intermediate Risk Prostate Cancer
University Health Network, Toronto7 enrolled1 locationNCT07339943
Recruiting
Phase 3

Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up

Thyroid CancerIntermediate Risk
Centre Francois Baclesse476 enrolled29 locationsNCT04290663
Recruiting
Not Applicable

MRI Guided Focal Laser Ablation of Prostate Cancer

Prostate CancerLow and Intermediate Risk Prostate Cancer
University Health Network, Toronto102 enrolled1 locationNCT03650595
Recruiting
Phase 2

Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients

High-Risk Acute Myeloid LeukemiaIntermediate Risk Acute Myeloid Leukemia
The First Affiliated Hospital of Soochow University60 enrolled1 locationNCT06394011